Actavis Pharma, Inc. Products: Prescription Medications Section

Page 1 of 68 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

Acarbose

Acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. CONTRAINDICATIONS: Acarbose is contraindicated in patients with known hypersensitivity to the drug. Acarbose is…

Actavis Pharma, Inc.18 October 2017

Acetasol HC (Hydrocortisone and Acetic Acid)

For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. CONTRAINDICATIONS: Hypersensitivity to any of the ingredients, herpes…

Actavis Pharma, Inc.18 December 2017

Acitretin

Acitretin capsules USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, acitretin capsules USP should be prescribed only by those knowledgeable in the systemic use of…

Actavis Pharma, Inc.30 January 2018

Actigall (Ursodiol)

Actigall is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the…

Actavis Pharma, Inc.24 December 2018

Acyclovir

Herpes Zoster Infections: Acyclovir is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir is indicated for the treatment of initial episodes and the…

Actavis Pharma, Inc.31 January 2020

Page 1 of 68 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Super Potency
Thu, 21 May 2020. Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent…
Biota Biosciences Issues Voluntary Nationwide Recall of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables Because They Were Marketed Without FDA Approval
Tue, 19 May 2020. Biota Biosciences is voluntarily recalling the following lots in the table below of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level.

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.